Entero healthcare solutions Limited has announced the resignation of a key senior management personnel, marking a significant change in its leadership structure. The company disclosed this development to stock exchanges in compliance with regulatory requirements.

Senior Management Departure

Mr. Sambit Mohanty, who served as President – Institutional Business, has tendered his resignation from the company. His departure represents a change in the senior management team responsible for the company's institutional business operations.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made through official communication to both BSE and NSE on March 11, 2026.

In his resignation letter, Mr. Mohanty expressed gratitude to the Board of Directors for their support and guidance during his tenure with the company. He specifically acknowledged the leadership team's contribution to his professional development.

Transition Details

The resignation follows standard corporate procedures, with the departing executive providing appropriate notice period. Mr. Mohanty will continue in his role until the close of business hours on March 31, 2026, ensuring a structured transition of responsibilities.

The company's disclosure indicates that this change in senior management personnel is part of normal corporate evolution, with the executive pursuing external career advancement opportunities. Entero Healthcare Solutions has completed all necessary regulatory filings regarding this leadership transition.

Entero Healthcare Solutions Limited announced its unaudited financial results for the third quarter of fiscal year 2026, ended December 31, 2025. The pharmaceutical trading company reported mixed performance with revenue growth offset by profitability challenges due to regulatory changes.

Financial Performance Overview

The company's standalone financial results showed revenue growth but significant impact on profitability. Key metrics demonstrate the effect of exceptional items on the quarter's performance.

Consolidated Results Show Strong Growth

On a consolidated basis, the company demonstrated robust revenue performance across its expanded operations. The consolidated results reflect the impact of recent acquisitions and organic growth.

Impact of New Labour Codes

The company's profitability was significantly affected by the implementation of new labour legislation. The Ministry of Labour and Employment consolidated multiple existing labour legislations into four unified Labour Codes, which became effective from November 21, 2025.

This regulatory change resulted in exceptional items worth ₹44.97 million (net of tax ₹33.65 million) for the standalone entity and ₹81.78 million (net of tax ₹61.14 million) on a consolidated basis. The company reassessed its employee benefit obligations in accordance with the revised definition of wages under the new framework.

Nine-Month Performance

For the nine months ended December 31, 2025, the standalone entity reported revenue of ₹2,693.09 million compared to ₹3,363.68 million in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹134.59 million versus ₹469.87 million in the previous year.

Corporate Actions and Strategic Updates

The board of directors approved several key decisions during their meeting held on February 12, 2026:

Employee Stock Options:

• Grant of 5,000 fresh employee stock options under the existing "Entero Employee Stock Option Plan 2023"
• Exercise price set at ₹804 per option
• Vesting period between 1-4 years from grant date
• Exercise period of 8 years from vesting date

Acquisition Updates:

• Cancelled proposed acquisitions of Khera Medisolutions Private Limited and AV Medisolutions Private Limited due to commercial reasons
• These acquisitions were previously announced in May and August 2025

Recent Acquisitions and Subsidiaries

During the nine months ended December 31, 2025, the company acquired controlling stakes in six entities, expanding its distribution network:

Subsequent to the quarter end, the company acquired 51.51% stake in Anand Chemiceuticals Private Limited on February 7, 2026.

IPO Proceeds Utilization

The company has fully utilized its IPO proceeds of ₹9,548.00 million as of December 31, 2025. The funds were deployed across debt repayment (₹1,425.00 million), working capital requirements (₹4,800.00 million), inorganic growth initiatives (₹2,370.00 million), and general corporate purposes (₹953.00 million).